167 related articles for article (PubMed ID: 35024732)
21. Keratoacanthoma and other types of squamous cell carcinoma with crateriform architecture: classification and identification.
Misago N; Inoue T; Koba S; Narisawa Y
J Dermatol; 2013 Jun; 40(6):443-52. PubMed ID: 23414327
[TBL] [Abstract][Full Text] [Related]
22. What Is a Solitary Keratoacanthoma? A Benign Follicular Neoplasm, Frequently Associated with Squamous Cell Carcinoma.
Ogita A; Ansai SI
Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679546
[TBL] [Abstract][Full Text] [Related]
23. Estimation of the volume-weighted mean nuclear volume discriminates keratoacanthoma from squamous cell carcinoma.
Binder M; Steiner A; Mossbacher U; Hunegnaw M; Pehamberger H; Wolff K
Am J Dermatopathol; 1998 Oct; 20(5):453-8. PubMed ID: 9790104
[TBL] [Abstract][Full Text] [Related]
24. Pattern of TGFbeta receptor 1 expression differs between kras-mutated keratoacanthomas and squamous cell carcinomas of the skin.
Berger F; Geddert H; Faller G; Werner M; Dimmler A
Pathol Res Pract; 2014 Sep; 210(9):596-602. PubMed ID: 24954139
[TBL] [Abstract][Full Text] [Related]
25. p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.
Kaabipour E; Haupt HM; Stern JB; Kanetsky PA; Podolski VF; Martin AM
Arch Pathol Lab Med; 2006 Jan; 130(1):69-73. PubMed ID: 16390241
[TBL] [Abstract][Full Text] [Related]
26. Proliferating cell nuclear antigen distribution in keratoacanthoma and squamous cell carcinoma.
Phillips P; Helm KF
J Cutan Pathol; 1993 Oct; 20(5):424-8. PubMed ID: 7507945
[TBL] [Abstract][Full Text] [Related]
27. The nuclear factor kappa B p50 subunit and cortactin as markers to distinguish between keratoacanthoma and well-differentiated squamous cell carcinoma.
Fujii M; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Oct; 36(7):788-92. PubMed ID: 21883393
[TBL] [Abstract][Full Text] [Related]
28. Aberrant p16, p53 and Ki-67 immunohistochemistry staining patterns can distinguish solitary keratoacanthoma from cutaneous squamous cell carcinoma.
Carr RA; Mesiano D; Heffron C; Radonic T; Wiggins J; Tso S; Agrawal R; Cheung E; Slater DN; Nichols L; Craig P
Pathology; 2023 Oct; 55(6):772-784. PubMed ID: 37573161
[TBL] [Abstract][Full Text] [Related]
29. Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant.
Sánchez Yus E; Simón P; Requena L; Ambrojo P; de Eusebio E
Am J Dermatopathol; 2000 Aug; 22(4):305-10. PubMed ID: 10949454
[TBL] [Abstract][Full Text] [Related]
30. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry.
Biesterfeld S; Josef J
Anticancer Res; 2002; 22(5):3019-23. PubMed ID: 12530035
[TBL] [Abstract][Full Text] [Related]
31. Keratoacanthoma and squamous cell carcinoma: study of PCNA and Le(Y) expression.
Tsuji T
J Cutan Pathol; 1997 Aug; 24(7):409-15. PubMed ID: 9274958
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and follow-up of keratoacanthoma-like lesions: clinical-histologic study of 43 cases.
Magalhães RF; Cruvinel GT; Cintra GF; Cintra ML; Ismael AP; de Moraes AM
J Cutan Med Surg; 2008; 12(4):163-73. PubMed ID: 18627696
[TBL] [Abstract][Full Text] [Related]
33. Crater/ulcerated form of infundibular squamous cell carcinoma: A possible distinct entity as a malignant (or high-grade) counterpart to keratoacanthoma.
Misago N; Inoue T; Nagase K; Tsuruta N; Tara-Hashimoto A; Kimura H; Takahara K; Narita T; Narisawa Y
J Dermatol; 2015 Jul; 42(7):667-73. PubMed ID: 25854192
[TBL] [Abstract][Full Text] [Related]
34. Distinguishing Keratoacanthoma from Well-Differentiated Cutaneous Squamous Cell Carcinoma Using Single-Cell Spatial Pathology.
Veenstra J; Ozog D; Loveless I; Adrianto I; Dimitrion P; Subedi K; Friedman BJ; Zhou L; Mi QS
J Invest Dermatol; 2023 Dec; 143(12):2397-2407.e8. PubMed ID: 37419445
[TBL] [Abstract][Full Text] [Related]
35. Plasmacytoid dendritic cells in keratoacanthoma and squamous cell carcinoma: A blinded study of CD123 as a diagnostic marker.
Fraga GR; Chow P
J Cutan Pathol; 2020 Jan; 47(1):17-21. PubMed ID: 31449667
[TBL] [Abstract][Full Text] [Related]
36. Natural course of keratoacanthoma and related lesions after partial biopsy: clinical analysis of 66 lesions.
Takai T; Misago N; Murata Y
J Dermatol; 2015 Apr; 42(4):353-62. PubMed ID: 25676096
[TBL] [Abstract][Full Text] [Related]
37. Keratoacanthoma of the conjunctiva - case report and review of the literature.
Szabo BA; Şovrea AS; Bartoş DM; Bartoş A; Georgiu C
Rom J Morphol Embryol; 2017; 58(4):1605-1609. PubMed ID: 29556663
[TBL] [Abstract][Full Text] [Related]
38. Proliferating cell nuclear antigen immunostaining in keratoacanthoma and squamous cell carcinoma of the skin.
Royds JA; Stephenson TJ; Silcocks PB; Bleehen SS
Pathologica; 1994 Dec; 86(6):612-6. PubMed ID: 7617390
[TBL] [Abstract][Full Text] [Related]
39. Computer Image Analysis Reveals C-Myc as a Potential Biomarker for Discriminating between Keratoacanthoma and Cutaneous Squamous Cell Carcinoma.
Fan X; Niu X; Wu Z; Yao L; Chen S; Wan W; Huang B; Qi RQ; Zhang T
Biomed Res Int; 2022; 2022():3168503. PubMed ID: 36051475
[TBL] [Abstract][Full Text] [Related]
40. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
